key: cord-0862956-kilmkw8z
authors: Coluccia, Antonella; Marchesini, Emanuela; Giuffrida, Anna Chiara; Rivolta, Gianna Franca; Ricca, Irene; Zanon, Ezio; Luciani, Matteo; De Cristofaro, Raimondo; Coppola, Antonio; Rocino, Angiola
title: Addressing the impact of SARS‐CoV‐2 infection in persons with congenital bleeding disorders: The Italian MECCOVID‐19 study
date: 2021-05-13
journal: Haemophilia
DOI: 10.1111/hae.14331
sha: 3f930b05d4af01621fb2ccc04fd63a73ac0b0259
doc_id: 862956
cord_uid: kilmkw8z

nan

On the other hand, the scientific community is deeply involved to fill the numerous pathophysiological and clinical knowledge gaps. was set up in Madrid, Spain by a telephone survey. 6 Suggestive symptoms were reported in 42 patients, but SARS-CoV-2 infection was confirmed by RT-PCR only in 6, accounting for a cumulative incidence of 1.73%. All patients showed a mild course of the disease, not requiring hospitalization. 6 Restrictions due to the lockdown and limited access to diagnostic tests in the first phase of pandemic clearly affect these data. Furthermore, larger collections of data are needed to address the intriguing issue of the impact of CAC and the related hypercoagulability in infected persons suffering from a congenital condition of hypocoagulability. Indeed, a letter by Iranian authors questioned whether CBD patients could somehow be spared from thrombotic complications. In a series of 9 CBD patients, a single thrombotic event was reported, occurring in a young type 1 von Willebrand disease patient needing IC admission due to severe COVID-19. 7 The authors concluded that patients with moderate to severe CBD with COVID-19 appear to be less likely to have a hypercoagulable state. 7 Few data are available also concerning the bleeding risk in patients with CBDs and COVID-19. In the Iranian series, two patients experienced bleeding. 7 A severe abdominal hematoma in a woman with inherited FXIII deficiency and severe cough due to COVID-19 has been reported. She was able to receive LMWH thromboprophylaxis after treatment of acute bleeding and prolonged prophylaxis with FXIII concentrate. 8 LMWH was used in a patient with severe haemophilia A on emicizumab prophylaxis and COVID-19, 9 as well in a patient with mild haemophilia A hospitalized because of acute respiratory failure, in whom, consistent with the hyperinflammatory state, high FVIII levels were found. 10 Both these patients did not experience thrombotic or haemorrhagic complications. However, the safety of LMWH in CBD patients with COVID-19 and indications about concomitant haemostatic prophylaxis are still uncertain, poorly supported by clinical data.

In light of these considerations, the urgent need to perform ad hoc clinical studies in patients with haemophilia and other CBDs infected by SARS-CoV-2 emerged. These patients are carefully monitored by HCs for their bleeding disorder and the related or unrelated co-morbidities, therefore accurate information can be retrieved and prospective follow-up can be planned. Moreover, national/regional registries of CBD patients are available for epidemiological assess- Table 1 . Although most patients were asymptomatic or had mild/moderate respiratory symptoms, at variance with the Spanish report, 6 In the AICE study, all CBD patients registered at the HCs at the COVID-19 outbreak are eligible and will be asked to be enrolled, irrespective of age and CBD severity, at routine visits or by telematic communications. At enrolment, patients' demographic data, CBD history, treatment and co-morbidities will be registered.

Moreover, specific case report forms will collect data about exposition to SARS-CoV -2 infection in the retrospective phase (February 2020-enrolment), including possible symptoms of disease, close contacts with infected individuals and quarantine, diagnostic tests performed (antigenic or PCR nasopharyngeal swabs, serologic tests for anti-SARS-CoV-2 antibodies). In patients diagnosed with 

Confronting COVID-19: issues in hemophilia and congenital bleeding disorders

Clinical trials and haemophilia during the COVID-19 pandemic: Madrid's experience

Interim guidance; coagulation products safety, supply and access (CPSSA) Committee of the World Federation of Hemophilia. Management of COVID-19-associated coagulopathy in persons with haemophilia

Immune-Mediated Coagulopathy in COVID-19 Infection

COVID-19, thromboembolic risk and thromboprophylaxis: learning lessons from the bedside, awaiting evidence

Registry of patients with congenital bleeding disorders and COVID-19 in Madrid

Patients with congenital bleeding disorders appear to be less severely affected by SARS-CoV-2: is inherited hypocoagulability overcoming acquired hypercoagulability of coronavirus disease 2019 (COVID-19)?

Severe bleeding in a patient with factor XIII deficiency and COVID-19

Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis

How haemophilia A impacts severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) treatment: a case report

Coauthors participating in the AICE MECCOVID-19 Study Group are listed in alphabetical order

Dorina Cultrera (Catania), Eva D'Attilio (Termoli), Grazia Delios (Ivrea)

Silvia Linari (Firenze), Maurizio Margaglione (Foggia), Renato Marino (Bari)

Ilaria Nichele (Vicenza)

Samantha Pasca (Padova)

Vincenzo Speciale (Taranto), Annarita Tagliaferri (Parma), Lelia Valdrè